Follow the Money to Medical Devices & Diagnostics
Spotlight on Lumicell, Inc.


Lumicell is a private US company that develops technologies that enable surgeons to see cancerous cells left behind before concluding surgical removal of a malignant tumor. It raised $28.7 million in the completion of a venture capital investment as reported in the PharmSource Lead Sheet on December 14, 2017.

Corporate Highlights

  • Lumicell was founded in 2008
  • Corporate Headquarters: Wellesley, MA

Sourcing Opportunities

  • Lumicell plans to use the proceeds to support the clinical development of its LUM intra-operative image-guidance system:

Device: LUM Imaging SystemTM
Development Phase: Pilot studies
Medical Specialty: Oncology; Surgery
Purpose: Diagnostic – in vivo/Imaging devicel
Type: System/System accessory
Description: A lightweight handheld single-cell detection imaging device with a wide field of view and a cancer-specific molecular imaging agent. The system enables surgeons to detect residual cancer cells in real time within the tumor bed.

Medical Device & Diagnostics Pipeline1

Product Candidate Indication Medical Specialty Purpose Type Status
LUM Imaging System Breast Cancer Oncology; Surgery Diagnostic – in vivo/Imaging device System/System accessory Pilot studies

 1Source: PharmSource Lead Sheet

Contact Information

Lumicell, Inc. Key Officers
80 William Street, Suite 260 Kelly Londy, CEO
Wellesley, MA 02481 USA Jorge Ferrer, PhD, SVP, R&D
Web: Felix Geissler, CMO
Phone: +1-781-684-0218 David Strasfeld, PhD, Director, R&D

Related posts:
Follow the Money to Pharmaceutical Opportunities – Spotlight on Fusion Pharmaceuticals, Inc.
Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on ARMO BioSciences, Inc.

Follow the Money to Pharmaceutical Opportunities – Spotlight on CymaBay Therapeutics

Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

More posts by Scotty Chung-Siu